Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
<h4>Background</h4>The current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC. We conducted a systematic review to determine whether neoadjuvant chemotherapy plus targeted therapy results in...
Main Authors: | Sudpreeda Chainitikun, Jose Rodrigo Espinosa Fernandez, James P Long, Toshiaki Iwase, Kumiko Kida, Xiaoping Wang, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T Ueno |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0250057 |
Similar Items
-
Update on systemic treatment for newly diagnosed inflammatory breast cancer
by: Sudpreeda Chainitikun, et al.
Published: (2021-03-01) -
The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy
by: Toshiaki Iwase, et al.
Published: (2021-02-01) -
Targeting Signaling Pathways in Inflammatory Breast Cancer
by: Xiaoping Wang, et al.
Published: (2020-09-01) -
Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer
by: Kumiko Kida, et al.
Published: (2020-10-01) -
Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
by: Hitoshi Inari, et al.
Published: (2020-09-01)